Cross-agency comparison: 🇪🇺 EMA leads with 84 documents in 90 days

FDA vs EMA vs MHRA vs Health Canada — who's most active?

The comparison suggests that EMA is currently the most active and document-rich environment, with MHRA and Health Canada also generating a meaningful level of regulatory output, while FDA appears comparatively quieter in this 90-day window. Sponsors should consider that this may indicate faster-moving guidance, higher interpretive churn, or more frequent procedural updates in Europe and Canada, which could make those markets more demanding for dossier maintenance and local regulatory tracking. For global filing strategy, this could suggest prioritizing regulatory intelligence and submission readiness resources where the pace of change is highest, rather than treating all markets as equally dynamic. Companies planning synchronized multi-market launches may want to build more flexibility into EU- and UK-facing workstreams, because uneven regulatory activity can create timing asymmetries and force last-minute adaptation of core filing packages.